Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

BIO-TECHNE CORPORATION

(TECH)
  Report
Real-time Estimate Cboe BZX  -  09:59 2022-12-05 am EST
81.34 USD   -3.96%
07:01aBIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION TOOL FOR IMAGING MITOCHONDRIA IN LIVE AND FIXED CELLS
PR
12/02Bio-techne and oxford nanopore technologies partner to bring innovative reproductive health and carrier screening solutions to the market
AQ
12/01Bio-Techne Teams Up With Oxford Nanopore Technologies for Reproductive Health Testing Projects
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Bio-Techne Corporation Enters into Credit Agreement with BMO Harris Bank N.A

09/07/2022 | 06:32am EST

On August 31, 2022, Bio-Techne Corporation entered into a Credit Agreement with the lenders party thereto, BMO Harris Bank N.A., Swing Line Lender and a Lender and the guarantors party thereto. The Credit Agreement provides for a revolving credit facility of $1 billion, which can be increased by an additional $400 million subject to certain conditions. Borrowings under the Credit Agreement may be used for working capital and expenditures of the Company and its subsidiaries, including financing permitted acquisitions.

Borrowings under the Credit Agreement bear interest at a variable rate. For base rate loans, the interest rate is equal to the sum of the applicable margin, which is established based on the Total Leverage Ratio for the most recently completed fiscal quarter, plus the base rate as established in the agreement. The base rate is the rate per annum equal to the greatest of: BMO's prime commercial rate, the sum of the Federal Funds Rate for such day plus 1/2 of 1.00%, and Adjusted term SOFR for a one-month interest period in effect two US Government Securities Business Days prior to such day plus 1.00%.

For SOFR loans, the interest rate is equal to the sum of the applicable margin, which is established based on the Total Leverage Ratio for the most recently completed fiscal quarter, plus the adjusted term SOFR applicable for such interest period. For Swing loans, the interest rate is equal to the sum of the applicable margin for base rate loans and the base rate. The Credit Agreement requires quarterly payments with respect to base rate loans and swing loans if the swing loan bears interest by reference to the base rate.

Payments are required at the end of each interest period with respect to SOFR loans and swing loans if the swing loan bears interest by reference to the Swing Line Lender's Quoted Rate. If such interest period is longer than three months, payments are required on each date occurring every three months after the commencement of such interest period. The Credit Agreement matures on August 31, 2027.

The Credit Agreement contains customary restrictive and financial covenants, including without limitation, covenants requiring the Company to pay certain fees, maintain, at the end of each fiscal quarter, a minimum interest coverage ratio of no less than 3.00 to 1.00 and maintain, at the end of each fiscal quarter, a maximum total funds debt to EBITDA ratio of no greater than 3.50 to 1.00, and covenants prohibiting the Company from, among other things, creating, incurring or assuming additional indebtedness, creating certain liens on any of its properties or assets, selling, leasing or transferring any of its properties or assets, with certain exceptions, including sales of inventory and equipment in the ordinary course of business and entering into certain merger, consolidation or other reorganization transactions with, or acquiring all or a substantial portion of the assets or equity interests of, any person or entity, subject to certain permitted acquisitions, in each case subject to certain exceptions. There is an option amend the Credit Agreement to convert to a Sustainability Linked Loan by agreement of the parties, with a corresponding small reduction in the commitment fee and variable rate. The Credit Agreement also contains customary events of default.

If an event of default under the Credit Agreement occurs and is continuing, then the lenders may declare any outstanding obligations under the Credit Agreement immediately due and payable and the lenders will have the right to terminate the Credit Agreement. Each of the Company's material domestic subsidiaries entered into the Credit Agreement as guarantors of the Company's obligations under the Credit Agreement. At the closing on August 31, 2022, the Company borrowed approximately $350 million pursuant to the Credit Agreement for working capital and for payment of outstanding debt under the Company's prior credit agreement.


ę S&P Capital IQ 2022
All news about BIO-TECHNE CORPORATION
07:01aBIO-TECHNE RELEASES MITOBRILLIANT™ FLUORESCENT DYES, PROVIDING A NEXT-GENERATION ..
PR
12/02Bio-techne and oxford nanopore technologies partner to bring innovative reproductive he..
AQ
12/01Bio-Techne Teams Up With Oxford Nanopore Technologies for Reproductive Health Testing P..
MT
11/30BIO-TECHNE CORPORATION : SPLIT: 4 of 1
FA
11/29Bio-Techne to Seek M&A
CI
11/29Transcript : Bio-Techne Corporation Presents at 5th Annual Evercore ISI Healt..
CI
11/28BIO-TECHNE TO PRESENT AT THE FIFTH ANNUAL EVERCORE ISI HealthCONx CONFERENCE
PR
11/17Transcript : Bio-Techne Corporation Presents at Stephens Annual Investment Co..
CI
11/17Namocell Highlighted in Nature Publication for Efficient Single Cell Cloning of Human P..
CI
11/17Namocell highlighted in nature publication for efficient single cell cloning of human p..
PR
More news
Analyst Recommendations on BIO-TECHNE CORPORATION
More recommendations
Financials (USD)
Sales 2023 1 202 M - -
Net income 2023 293 M - -
Net cash 2023 176 M - -
P/E ratio 2023 48,1x
Yield 2023 0,52%
Capitalization 13 294 M 13 294 M -
EV / Sales 2023 10,9x
EV / Sales 2024 9,44x
Nbr of Employees 3 000
Free-Float 99,2%
Chart BIO-TECHNE CORPORATION
Duration : Period :
Bio-Techne Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BIO-TECHNE CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 12
Last Close Price 84,69 $
Average target price 105,08 $
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Charles R. Kummeth President, Chief Executive Officer & Director
James T. Hippel Chief Financial Officer
Robert V. Baumgartner Chairman
Brenda Swierenga Furlow Secretary & Chief Compliance Officer
Randolph C. Steer Independent Director
Sector and Competitors
1st jan.Capi. (M$)
BIO-TECHNE CORPORATION-34.52%13 294
MODERNA, INC.-28.20%70 055
IQVIA HOLDINGS INC.-22.83%40 441
LONZA GROUP AG-33.82%39 802
ALNYLAM PHARMACEUTICALS, INC.38.22%28 838
SEAGEN INC.-20.82%22 727